Not Yet RecruitingNot Applicable

CVCs Versus Midline Catheters

United States100 participantsStarted 2026-06

Plain-language summary

The goal of this clinical trial is to learn if midline catheters can reduce adverse patient outcomes in adult patients requiring a single vasopressor. The main questions the study aims to answer are: * Do midline catheters reduce the rates of catheter-related bloodstream infections as compared to central venous catheters? * Do midline catheters reduce the rates of deep venous thrombosis as compared to central venous catheters? Researchers will compare midline catheters to central venous catheters to see if there is a reduction in these events. Participants will be randomized to the midline catheter group or the central venous catheter group. The catheters will be part of standard of care for vasopressor therapy. The participants will be followed for 30 days.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients over 18 years of age being treated in the Emergency Department at Jacobi Medical Center * Have an upper extremity (left or right arm) that can accept a midline catheter * Able to provide consent (patient or health care proxy) * Clinical team believes the patient will require inpatient admission at the time of needing intravenous access * Requires a central line or midline catheter as an expected requirement of care * Patients requiring a single vasopressor due to hypotension Exclusion Criteria: * Patients in cardiac arrest (prior to achieving ROSC) * Patients with infection or burns at both upper extremities * Patient expected to be discharged from the hospital within 24 hours * Prisoner * Pregnancy * Children less than 18 years of age * The patient is known or is suspected to be allergic to materials contained in the device * Patients known to have bacteremia * Patients with existing central venous catheter * Patients without the ability to consent (or no health care proxy to consent)

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Number of catheter related bloodstream infections (CRBSI) within 28 days of placement

Timeframe: Up to 28 days from placement of catheter

Trial details

NCT IDNCT06884176

SponsorAlbert Einstein College of Medicine

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-06

Contact for this trial

Ariella S Gartenberg, MD

2017871762 ariella.applebaum@gmail.com

View on ClinicalTrials.gov More Central Venous Catheter trials